Background: Individuals with an extremely rare inherited condition, termed Congenital Insensitivity to Pain (CIP), do not feel pain in response to noxious stimuli. Variants in SCN9A, encoding the transmembrane voltage-gated sodium channel Na v 1.7, have previously been reported in subjects with CIP accompanied by anosmia, which are typically transmitted in a recessive pattern. Functional characterisations of some of these SCN9A mutations show that they result in complete loss-of-function of Na v 1.7. Methods: In a consanguineous family we performed whole exome sequencing of three members who have a diagnosis of CIP and one unaffected family member. The functional effects of the segregating variant in SCN9A were determined using patch clamp electrophysiology in human embryonic kidney (HEK) 293 cells transfected with the variant. Results: We found that each CIP subject was homozygous for a putatively nonsense variant, R1488*, in SCN9A. This variant was reported elsewhere in a subject with CIP, though the functional effect was not determined. Using electrophysiology, we confirm that this variant results in a complete loss-of-function of Na v 1.7. Conclusions: We confirm through electrophysiological analysis that this R1488* variant in SCN9A results in complete loss-of-function of Na v 1.7, which is consistent with reports on other variants in this gene in subjects with CIP.
Background
All mammals need to detect and avoid noxious stimuli to protect their tissue from damage; this is achieved via nociception. To date, over 30 loss-of-function variants in SCN9A, encoding the Na v 1.7 sodium channel, have been identified and reported to cause Congenital Insensitivity to Pain (CIP), a very rare autosomal recessive disorder characterised by the complete absence of pain perception [1, 2] . Conversely, gain-of-function variants in SCN9A have been reported in patients with rare extreme pain disorders such as inherited erythromyelgia and paroxysmal episodic pain disorder [3] .
CIP is present from birth with painless injuries evident from early in infancy such as damage to the tongue and lips caused by biting. Patients are often anosmic but otherwise have normal sensory modalities. Perception of passive movement, joint position, and vibration are normal, as are tactile thresholds and light touch perception. Reflexes and autonomic responses are also normal. The disorder is considered to be an irreversible disorder of peripheral pain sensing neurons; why these neurons are so reliant on Na v 1.7, however, is not clear.
We describe a consanguineous three-generation pedigree in which CIP was observed in three individuals over two generations. The primary hypothesis was that the causative variant would be homozygous in the affected family members, given the consanguinity and the recessive pattern of inheritance observed. Exome sequencing was employed to identify variants that segregate accordingly. We identified a homozygous nonsense variant R1488* in SCN9A in all three affected subjects and showed that this variant results in complete loss-of-function of the Na v 1.7 ion channel.
Methods

Families and sampling
The index case (Fig. 1a, 1 ) was described previously [4] . She presented with a history of pain free wounds, burns, bone fractures, and appendicitis and experienced no pain during childbirth. In addition, this individual had other neurological dysfunctions: anosmia, aguesia, unexplained hyperthermia and impaired cold and warm perception. The painless phenotype was inherited recessively whereby her only son was affected but two daughters were unaffected. The index case and her husband (Fig. 1a, 2) were first cousins -he is the son of her mother's brother. The son (Fig. 1a, 4 ) had a history of painless burns, wounds, self-mutilation, fractures and infections. He was also anosmic and was reported to be hyperactive. The third affected family member was a sister (Fig. 1a, 3 ) of the index case. She experienced similar painless, noxious events characteristic of CIP: wounds, burns, self-mutilation of the lips and was also anosmic. None of the affected subjects showed any cognitive or motor dysfunction. The two affected females reported residual pain experiences of differing severities. The index case reported one episode of a tension-type headache. Her sister (Fig. 1a, 3) reported bowel pain and some pain perception since adolescence and following pregnancy, she reported being hypersensitive to pain stimuli and to odourants. The son had no reports of residual pain but was in his first decade of life at the time of reporting.
The husband (Figs. 1a and 2 ) and all other relatives shown in the pedigree reported that they experience pain in a 'typical' manner. DNA was available from the husband but not from any of the other unaffected family members.
Genomic DNA was isolated from peripheral blood by standard methods.
Exome capture and analysis
Genomic DNA was prepared for whole exome sequencing using Agilent SureSelect version 4, 51 megabase (Mb) capture kit following the manufacturer's protocol (Agilent Technologies). These samples were then sequenced using the Illumina HiSeq 2000 platform (Illumina, Inc., San Diego, CA; paired-end: 2x100bp) by Perkin Elmer Next Generation Sequencing and Analysis Center (Branford, CT). The reads generated were mapped to NCBI Human Reference (GRCh37; hg19) using Burrows-Wheeler Aligner (BWA) v0.5.9 [5] . The alignment files for each sample were sorted and indexed by SAMtools [6] to create the final Binary Alignment Map (BAM) files, which is a compressed binary version of a Sequence Alignment Map (SAM) file. Variant discovery tool for high-throughput sequencing data Genome Analysis Toolkit (GATK) v1.0.5777 [7] was run using default values. Variant functional annotation tool ANNOVAR [8] was adopted for genomic annotation. To predict the effects of coding non-synonymous variants on protein function, we used both Sorting Intolerant From Tolerant (SIFT) [9] and Polymorphism Phenotyping version 2 (Polyphen-2) [10] in our search for the potential causal variants.
Minor allele frequency information was downloaded from online databases of genetic variants: NCBI dbSNP, 1000 genomes [11] , and NHLBI Exome Sequencing Project (ESP) Exome Variant Server [12] and were used in the variant filtering process. The upper minor allele frequency cut-off was 1%. Individual variants were evaluated in more detail by visualization of the BAM files with the Integrative Genomics Viewer (IGV) [13] .
Molecular biology and cell line generation
The human Na v 1.7 expression construct in the pLNCX2 retroviral vector (Clontech) has been described previously [14] . Polymerase Chain Reaction (PCR)-based site-directed mutagenesis was performed to introduce a stop codon at R1488 of the Na v 1.7 protein. Stable cell lines expressing Na v 1.7 WT and Na v 1.7 R1488* were produced as follows. Briefly, retroviruses were generated from sequence verified wild type and mutant constructs by transfecting the constructs into a GP2 packaging cell line (Clontech) using Lipofectamine 2000 reagent (Invitrogen). Retroviruses were harvested 48 h later and purified by centrifugation at 1500 g to remove residual GP2 cells. Native voltage-gated sodium channels comprise of large, channel forming, 24 transmembrane domain α-subunits. In a neuronal context, these α-subunits form co-complex with β-subunits, which aid the expression and trafficking of the α-subunit to the plasma membrane. To reproduce this cellular process, β1 and β2 subunits were co-expressed. The viruses were transduced into HEK-293 cells co-expressing a chimera of Na v β1 and Na v β2 auxiliary subunits. Stable cell populations were generated by G418 (800 μg/ml) selection. The control is the wild type SCN9A gene which was stably expressed in HEK-293 cells using the same procedures.
Patch-clamp electrophysiology
All recordings were performed at room temperature in HEK-293 cells expressing human Na V 1.7. Patch-clamp recordings were made using a Multiclamp 700A amplifier and digitised by a Digidata 2000. Glass borosilicate pipettes were used (typical R pip of 2-5 MΩ resulting in uncompensated R series < 8 MΩ). Cells were recorded in "reduced sodium" extracellular solution (avoiding voltage errors resulting from large currents) containing (in mM) NaCl (30), ChoCl (80) KCl (4), CaCl2 (1.8), MgCl2 (1), HEPES (10), glucose (5); pH was adjusted to 7.4 with NaOH. Pipettes were filled with intracellular solutions (in mM) KCl (140), MgCl2 (1.6), MgATP (2.5), NaGTP (0.5), EGTA (2), HEPES (10); pH was adjusted to 7.3. An activation protocol was used whereby cells were voltage-clamped at a holding potential of −120 mV followed by a 50 ms step to the activating step (−90 mV to + 40 mV, 10 mV steps). The peak inward current at each activating step was quantified and presented as current-voltage curves.
qPCR Expression of SCN9A messenger RNA was assessed in the stable cell line used in this study as previously reported [15] . Taqman qPCR primers were used for SCN9A (Hs00161567) and for the housekeeping gene GAPDH (Hs02758991_g1). SCN9A expression was expressed as a WT exhibited a clear current-voltage relationship typical for voltage-gated sodium channels (− 13.0 ± 0.8 mV, n = 10). c Quantitative PCR shows that both Na v 1.7 R1488* and Na v 1.7 WT cells express comparable amount of mRNA demonstrating that the variant is likely to be non-functional at the protein level. No mRNA is detectable in a parental cell line ratio of GAPDH. A HEK-293 parental cell line not transfected with SCN9A was used as a negative control.
Results
Identification of a segregating SCN9A variant
After mapping all the reads, we identified that 94% of the targeted region of 51 million bases is covered at least once. Eighty-two percent of targeted region is covered for 20× or more. Each of the four individuals had >8000 putatively functional (nonsynonymous, nonsense or frameshift) variants. To filter out the non-causal variants, we first removed the homozygous variants found in the unaffected subject, followed by the homozygous variants not shared by all three affected subjects. The same filtering process was applied to heterozygous variants. As a result, we obtained 303 variants that were shared by all three affected subjects, but not by unaffected subject. Of these 303 variants, 11 variants have a minor allele frequency <1%, and three of these were homozygous in all three affected subjects and heterozygous in the unaffected subject. All three variants are co-located within 1.9 Mb on chromosome 2 (Fig. 1b) . One of the three variants, an SCN9A nonsense variant p.(Arg1488*) or p.(R1488*) was found to be homozygous in all affected subjects and was in heterozygous form in the unaffected subject (Fig. 1c) ), and both were co-transfected with Na v β1 and Na v β2 to ensure membrane trafficking of the mature channel. Cell lines expressing Na v 1.7 WT and Na v 1.7 R1488* were assessed by whole-cell patch-clamp electrophysiology using a voltage-activation protocol (Fig. 2a) . Cells expressing Na v 1.7 WT exhibited large inward currents in response to depolarising voltages more positive than −40 mV with a V 1/2 of activation of − 13.0 ± 0.8 mV (n = 10, Fig. 2b) . Conversely, the same voltage protocols elicited no inward currents in Na v 1.7 R1488* cells. When measuring inward currents at 0 mV there were no detectable currents in Na v 1.7 R1488* cells (0/20 cells, >100 pA); whereas there were clear inward currents in Na v 1.7 WT cells (16/20 cells, >100pA). To ensure both cell lines were expressing SCN9A mRNA at comparable levels we assessed expression using qPCR; both cell lines expressed identical levels of mRNA demonstrating that the lack of functional responses are not due to mRNA expression levels (Fig. 2c) . The parental line in Fig. 2c is the non-transfected HEK-293 cell line.
Taken together, these data demonstrate that the truncation of Na v 1.7 at R1488 results in a completely non-functional channel. Using the "50 nucleotide" rule which forms the basis of nonsense mediated decay (NMD) classifier [17] , the R1488* variant is predicted to result in nonsense mediated decay. It is located at position 4809 of 9768 nucleotides in the transcript within exon 25 out of 27, and so satisfies the criterion of being greater than 50 nucleotides from the last exon junction. Overall, our findings are consistent with previous reports of the role of Na v 1.7 ion channels in pain sensation.
Discussion
Here we identify a SCN9A CIP variant present in the homozygous state in three individuals with CIP and demonstrate for the first time that this variant results in complete loss-of-function of the ion channel Na v 1.7 encoded for by this gene. Electrophysiological analysis of the resulting Na v 1.7 R1488* ion channel yielded no functional responses in comparison to Na v 1.7 WT , demonstrating that the CIP subjects had deficient Na v 1.7 channels. This finding supports the body of human and mouse [18] evidence that knocking out SCN9A results in loss of pain perception. According to the annotation of Na v 1.7 in UniProt (http://www.uniprot.org), R1488 is located within the cytoplasmic topological domain between repeats III and IV. Despite the qPCR results showing that mRNA expression is at a comparable level for both the variant and the wild type, without CIP subject-derived cells or genome editing of a human cell line with this point mutation we cannot rule out that the loss-of-function effect that we have observed is driven by NMD as would be predicted. It would be interesting to determine whether homozygous carriers of this variant had very low or completely absent expression of the Na v 1.7 protein. Alternatively, these subjects may produce a truncated though inactive version of Na v 1.7.
We adopted a hypothesis-free approach and identified three putative causative rare homozygous variants. Variants in BGALT1 and TTC21B in addition to SCN9A were identified. However, the weight of evidence implicating SCN9A as a driver of CIP, along with the previous identification of this particular variant in a patient with CIP, and the functional evidence we present, strengthen the likelihood that CIP in this particular family is SCN9A-driven.
SCN9A-driven CIP is typically considered to be an immutable phenomenon, with patients suffering from lifelong painlessness accompanied by a lack of ability to smell. Intriguingly, the clinical features of the CIP patients do not entirely match with previously reported CIP caused by variants in SCN9A. The two affected females reported some residual pain experiences along with classical SCN9A-driven anosmia. One of the female subjects reported becoming hypersensitive to some painful stimuli following pregnancy and also regained hypersensitivity to odourants. A further example of an SCN9A-CIP patient experiencing pain is that of a female individual who began to experience neuropathic pain symptoms following pelvic fractures and an epidural haematoma [19] . We note that in this particular report the hip fracture was suffered as a consequence of bone weakening during pregnancy. So, similar to the case reported here, it appears that during pregnancy, dynamic changes can occur in the nervous system that compensate for a lack of SCN9A and return nociception and smell to the CIP individual.
A recent report has proposed that CIP associated with loss of Na v 1.7 causes analgesia via an increase in expression of the enkephalin precursor gene PENK. CIP in humans was shown to be substantially reversed by the opioid antagonist naloxone supporting this hypothesis [20] . It is possible that PENK, or indeed other regulatory genes of the opioid system, are altered during pregnancy and so may be part of the underlying mechanism of our observations. However this does not explain why the index case, and other reported CIP female patients, did not have the same experience and so further work is required to test this hypothesis.
Conclusion
This work demonstrates that the R1488* variant seen in patients with CIP results in complete loss-of-function of Na v 1.7, providing strong evidence that this variant causes the CIP phenotype. In addition, this finding provides further confidence-in-rationale for the therapeutic strategy of blocking Na v 1.7 for the treatment of pain.
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